289.3 🏥 內科專科考前版

289.3.1 Mechanistic Deep Dive

289.3.1.1 TOF Genetics

  • 22q11.2 deletion (DiGeorge syndrome) — 15-20% of TOF
  • NKX2.5 mutations
  • JAG1 mutations (Alagille)
  • Family hx in some

289.3.1.2 Embryology

  • Failed conotruncal septation
  • Right-anterior deviation of infundibular septum
  • Results in 4 anatomic features

289.3.1.3 Eisenmenger Pathology

  • Plexiform lesions in pulmonary arteries
  • Endothelial dysfunction, smooth muscle proliferation
  • Inflammation
  • Similar to other PAH causes but driven by chronic ↑ flow

289.3.2 Recent Trials & Updates

289.3.2.1 TPVR Long-Term Data

  • Melody and Harmony 10+ year data
  • Stenosis + endocarditis main complications
  • Re-intervention feasible

289.3.2.2 COMPASSION (2022) — Melody for ToF/PVR

  • Multicenter registry
  • Safety + efficacy data

289.3.2.3 EMPACT-MI Subgroup

  • ACHD with HF benefit similar to non-ACHD

289.3.2.4 Heart-Lung Transplant for Eisenmenger

  • Single-center long-term outcomes
  • Improved with modern immunosuppression

289.3.3 High-Yield Specialist Points

289.3.3.1 TPVR (Transcatheter Pulmonary Valve Replacement)

  • Melody (Medtronic): bovine jugular vein graft
  • Harmony (Medtronic): self-expanding for native RVOT
  • Edwards SAPIEN: balloon-expandable, off-label native
  • Indications: severe PR with RV dilation, dysfunction, arrhythmia
  • Bridge to surgical PVR
  • Complications: endocarditis, stent fracture, stenosis

289.3.3.2 Surgical PVR

  • Bioprosthetic preferred (avoid AC)
  • Durability ~ 10-15 years
  • Often need re-do

289.3.3.3 TOF + LV Dysfunction

  • Late LV dysfunction common
  • Associated with RV-LV interaction
  • GDMT same as standard HFrEF (ACEi/ARB/ARNI + β-blocker + MRA + SGLT2i)

289.3.3.4 Coarctation Post-Op Care

  • HTN despite repair (50%)
  • Lifelong CV risk: dissection, CAD, HF
  • BP control < 130/80
  • Aspirin
  • Lipid management
  • Lifelong CMR follow-up

289.3.3.5 Bicuspid AV + Coarctation

  • 50-80% of coarctation has BAV
  • Aortic root dilation
  • Screen first-degree relatives
  • Lifelong follow-up

289.3.3.6 TGA Late Issues

  • Mustard/Senning: baffle stenosis, baffle leak, atrial arrhythmia, sinus node dysfunction
  • Permanent pacer common
  • ICD for selected (sudden death risk)
  • TR (systemic AV valve) progressive
  • Eventual transplantation

289.3.3.7 ccTGA Management

  • GDMT for systemic RV
  • TR (systemic AV valve) surgery if severe
  • Pregnancy mWHO 3
  • Atrial arrhythmia ablation

289.3.3.8 Genetic Counseling in TOF

  • Recurrence risk: 3-5% in offspring (~ 10x baseline)
  • 22q11 testing
  • Family screening

289.3.3.9 Pregnancy in TOF

  • mWHO 2-3 depending on residual issues
  • Pre-pregnancy assessment with CPET
  • Severe PR + RV dysfunction increases risk
  • Multidisciplinary care

289.3.3.10 Eisenmenger + Iron

  • Iron deficiency in 25-30%
  • Despite high Hct, iron stores low
  • Iron supplementation if ferritin < 15-20
  • Avoid phlebotomy except symptomatic hyperviscosity

289.3.3.11 Sotatercept in PAH-CHD

  • STELLAR subgroup encouraging
  • Likely future approval

289.3.3.12 IE Prophylaxis in Eisenmenger

  • Class I for unrepaired cyanotic CHD
  • Dental, surgical procedures
  • Amoxicillin 2 g

289.3.4 Pearls

  • TOF: 4 features; modern survival > 90%; PR + VT + SCD = late issues
  • TPVR for severe PR: Melody, Harmony, SAPIEN
  • Coarctation: HTN persistence common; lifelong CV follow-up
  • D-TGA arterial switch: anatomical correction; coronary + neo-AV issues
  • Mustard/Senning + ccTGA: systemic RV → eventual failure
  • Eisenmenger: avoid pregnancy (30-50% maternal mortality); BREATHE-5 bosentan
  • 22q11 deletion (DiGeorge) in 15-20% of TOF